|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal,healthy stomach显示文摘AIM:To study the value of serum biomarker tests to differentiate between patients with healthy or diseased stomach mucosa:i.e.those with Helicobacter pylori(H pylori)gastritis or atrophic gastritis,who have a high risk of gastric cancer or peptic ulcer diseases.METHODS:Among 162 Japanese outpatients,pepsinogen-(Pg-)and(Pg)were measured using a conventional Japanese technique,and the European GastroPanel examination(Pg and Pg,gastrin-17 and H pylori antibodies).Gastroscopy with gastric biopsies was performed to classify the patients into those with healthy stomach mucosa,H pylori non-atrophic gastritis or atrophic gastritis.RESULTS:Pg-and Pg assays with the GastroPanel and the Japanese method showed a highly significant correlation.For methodological reasons,however,serum Pg-,but not Pg,was twice as high with the GastroPanel test as with the Japanese test.The biomarker assays revealed that 5%of subjects had advanced atrophic corpus gastritis which was also verified by endoscopic biopsies.GastroPanel examination revealed an additional seven patients who had either advanced atrophic gastritis limited to the antrum or antrum-predominant H pylori gastritis.When compared to the endoscopic biopsy findings,the GastroPanel examination classified the patients into groups with 'healthy' or 'diseased' stomach mucosa with 94% accuracy,95% sensitivity and 93% specifi city.CONCLUSION:Serum biomarker tests can be used to differentiate between subjects with healthy and diseased gastric mucosa with high accuracy. | Katsunori Iijima Yasuhiko Abe Ryosuke Kikuchi Tomoyuki Koike Shuichi Ohara Pentti Sipponen Tooru Shimosegawa | 2009 | World Journal of Gastroenterology2009，15，7： | 25 |
| 2 | Association of autoimmune type atrophic corpus gastritis with Helicobacter pylori infection显示文摘AIM:To study the association between Helicobacter pylori(H.pylori)infection and autoimmune type atrophic gastritis. METHODS:Twenty-three patients with different grades of atrophic gastritis were analysed using enzyme immunoassay-based serology,immunoblot-based serology,and histology to reveal a past or a present H.pylori infection.In addition,serum markers for gastric atrophy(pepsinogenⅠ,pepsinogenⅠ/Ⅱand gastrin)and autoimmunity[parietal cell antibodies(PCA), and intrinsic factor(IF),antibodies]were determined. RESULTS:Of the 14 patients with severe gastricatrophy,as demonstrated by histology and serum markers,and no evidence for an ongoing H.pylori infection,eight showed H.pylori antibodies by immunoblotting.All eight had elevated PCA and 4/8 also had IF antibodies.Of the six immunoblot-negative patients with severe corpus atrophy,PCA and IF antibodies were detected in four.Among the patients with low to moderate grade atrophic gastritis(all except one with an ongoing H.pylori infection),serum markers for gastric atrophy and autoimmunity were seldom detected.However,one H.pylori negative patient with mild atrophic gastritis had PCA and IF antibodies suggestive of a pre-atrophic autoimmune gastritis. CONCLUSION:Signs of H.pylori infection in autoimmune gastritis,and positive autoimmune serum markers in H.pylori gastritis suggest an etiological role for H.pylori in autoimmune gastritis. | Lea Irene Veijola Aino Mirjam Oksanen Pentti Ilmari Sipponen Hilpi Iris Kaarina Rautelin | 2010 | World Journal of Gastroenterology2010，16，1： | 10 |
| 3 | Low circulating levels of gastrin-17 in patients with Barrett's esophagus显示文摘AIM: To examine whether the fasting levels of serum gastrin-17 (G-17) are lower in Barrett's esophagus (BE)patients than in non-Barrett controls.METHODS: Nineteen patients with BE (presenting with a tubular segment ≥2 cm long in lower esophagus and intestinal metaplasia of incomplete type ('specialized columnar epithelium') in endoscopic biopsies from the tubular segment below the squamocolumnar junction were collected prospectively from outpatients referred to diagnostic gastroscopy. The controls comprised 199 prospectively collected dyspeptic outpatients without BE or any endoscopically visible lesions in the upper GI tract.Fasting levels of serum G-17 (G-17fast) were assayed with an EIA test using a Mab highly specific to amidated G-17. None of the patients and controls received therapy with PPIs or other antisecretory agents.RESULTS: The mean and median levels of G-17fast in serum were significantly lower (P = 0.001) in BE patients than in controls. The positive likelihood ratios (LR+) of low G-17fast to predict BE in the whole study population at G-17fast levels <0.5, <1, or <1.5 pmol/L were 3.5, 3.0,and 2.8, respectively. Among patients and controls with healthy stomach mucosa, the LR+ were 5.6, 3.8, and 2.6,respectively. In the whole study population, serum G-17 was below 2 pmol/L in 15 of 19 BE patients (79%). The corresponding prevalence was 66 of 199 (33%) in controls (P<0.001). The G-17fast was 5 pmol/L or more in only one of the 19 BE patients (5%). In controls, 76 of the 199 patients (38%) had such high serum G-17fast levels (P<0.01).CONCLUSION: Serum levels of G-17fast tend to be lower in native patients with BE than in healthy controls. | Pentti Sipponen Matti Vauhkonen Timo Helske Ilpo Kriinen Matti Hrknen | 2005 | World Journal of Gastroenterology2005，11，38： | 6 |
| 4 | Elevated pro-inflammatory and lipotoxic mucosal lipids characterise irritable bowel syndrome显示文摘AIM:To investigate the pathophysiology of irritable bowel syndrome(IBS)by comparing the global mucosal metabolic profiles of IBS patients with those of healthy controls.METHODS:Fifteen IBS patients fulfilling the Rome Ⅱcriteria,and nine healthy volunteers were included in the study.A combined lipidomics(UPLC/MS)and metabolomics(GC×GC-TOF)approach was used to achieve global metabolic profiles of mucosal biopsies from the ascending colon.RESULTS:Overall,lipid levels were elevated in patients with IBS.The most significant upregulation was seen for pro-inflammatory lysophosphatidylcholines.Other lipid groups that were significantly upregulated in IBS patients were lipotoxic ceramides,glycosphingolipids,and di-and triacylglycerols.Among the metabolites,the cyclic ester 2(3H)-furanone was almost 14-fold upregulated in IBS patients compared to healthy subjects(P=0.03).CONCLUSION:IBS mucosa is characterised by a distinct pro-inflammatory and lipotoxic metabolic profile.Especially,there was an increase in several lipid species such as lysophospholipids and ceramides. | Kajsa Kajander Eveliina Myllyluoma Sinikka Kyrnpalo Martin Rasmussen Pentti Sipponen Ismo Mattila Tuulikki Seppnen-Laakso Heikki Vapaatalo Matej Orei Riitta Korpela | 2009 | World Journal of Gastroenterology2009，15，48： | 5 |
| 5 | Infliximab in pediatric inflammatory bowel disease rapidly decreases fecal calprotectin levels显示文摘AIM: To study the response to infliximab in pediatric inflammatory bowel disease (IBD), as reflected in fecal calprotectin levels. METHODS: Thirty-six pediatric patients with IBD [23 Crohn's disease (CD), 13 ulcerative colitis (UC); median age 14 years] were treated with infliximab. Fecal calprotectin was measured at baseline, and 2 and 6 wk after therapy, and compared to blood inflammatory markers. Maintenance medication was unaltered until the third infusion but glucocorticoids were tapered off if the patient was doing well. RESULTS: At introduction of infliximab, median fecal calprotectin level was 1150 μg/g (range 54-6032 μg/g). By week 2, the fecal calprotectin level had declined to amedian 261 μg/g (P < 0.001). In 37% of the patients, fecal calprotectin was normal (< 100 μg/g) at 2 wk. By week 6, there was no additional improvement in the fecal calprotectin level (median 345 μg/g). In 22% of the patients, fecal calprotectin levels increased by week 6 to pretreatment levels or above, suggesting no response (or a loss of early response). Thus, in CD, the proportion of non-responsive patients by week 6 seemed lower, because only 9% showed no improvement in their fecal calprotectin level when compared to the respective figure of 46% of the UC patients (P < 0.05). CONCLUSION: When treated with infliximab, fecal calprotectin levels reflecting intestinal inflammation normalized rapidly in one third of pediatric patients suggesting complete mucosal healing. | Anssi Hmlinen Taina Sipponen Kaija-Leena Kolho | 2011 | World Journal of Gastroenterology2011，17，47： | 3 |
| 6 | Faecal calprotectin and lactoferrin are reliable surrogate markers of endoscopic response during Crohn’s disease treatment显示文摘 | Taina Sipponen Clas-Gö ran AF Bjö rkesten Martti Fä rkkilä Hannu Nuutinen Erkki Savilahti Kaija-Leena Kolho | 2010 | Scandinavian Journal of Gastroenterology2010，，3： | 2 |
| 7 | Mucosal healing at 3 months predicts long-term endoscopic remission in anti-TNF-treated luminal Crohn’s disease显示文摘 | Clas-G?ran af Bj?rkesten Urpo Nieminen Taina Sipponen Ulla Turunen Perttu Arkkila Martti F?rkkil? | 2013 | Scandinavian Journal of Gastroenterology2013，，5： | 2 |
| 8 | OLGA staging for gastritis: A tutorial显示文摘 | M. Rugge P. Correa F. Di Mario E. El-Omar R. Fiocca K. Geboes R.M. Genta D.Y. Graham T. Hattori P. Malfertheiner S. Nakajima P. Sipponen J. Sung W. Weinstein M. Vieth | 2008 | Digestive and Liver Disease2008，，8： | 2 |
| 9 | Fecal calprotectin concentration predicts outcome in inflammatory bowel disease after induction therapy with TNFα blocking agents显示文摘 | Pauliina Molander Clas‐G?ran af Bj?rkesten Harri Mustonen Johanna Haapam?ki Matti Vauhkonen Kaija‐Leena Kolho Martti F?rkkil? Taina Sipponen | 2012 | Inflamm Bowel Dis2012，，11： | 2 |
| 10 | Delayed rise in incidence of gastric cancer in females results in unique sex ratio (M/F) pattern: etiologic hy- pothesis 显示文摘 | Sipponen P Correa P | 2002 | Gastric Cancer2002，5，4： | 1 |
| 11 | Local dressings for pressure ulcers: what is the best tool to apply in primary and second care? 显示文摘 | Lohi J Sipponen A Jokinen JJ | 2010 | J Wound Care2010，19，3： | 1 |
| 12 | Clinical impact of routine biopsies of the gastric antrumandbody显示文摘 | Sipponen P Stolte M | | 0，，： | 1 |
| 13 | Correlation between the allelic distribution of STRs in a Finnish population and phenotypically different gastrointestinal tumours:a study using four X-chromosomal markers (DXS7423,DXS8377,ARA,DXS101)显示文摘 | Vauhkonen H Vauhkonen M Sipponen P | 2004 | Ann Hum Genet2004，68，6： | 1 |
| 14 | Diagnostics and prognostics of inflammatory bowel disease with fecal neutrophil-derived biomarkers calprotectin and lactofen'in 显示文摘 | Sipponen T | 2013 | Dig Dis2013，31，34： | 1 |
| 15 | Fecal calprotectin,lactoferrin,and endoscopic disease activity in monitoring anti-TNF-alpha therapy for Crohn's disease显示文摘 | Sipponen T Savilahti E Karkkainen P | | 0，，10： | 1 |
| 16 | Comparison of nefopam and pethidine in postoperative pain显示文摘 | Tigerstedt I Sipponen J Tammisto T | 1977 | Br J Anaesth1977，49，11： | 1 |
| 17 | Diagnosis of atrophic gastritis from a serum sample显示文摘 | Sipponen P Harkonen M Alanko A | 2003 | J Minerva Gastroenterol Dietol2003，49，1： | 1 |
| 18 | Clinical impact of routine biopsies of the gastric antrum and body显示文摘 | Sipponen P Stelte M | 1997 | Endoscopy1997，29，： | 1 |
| 19 | Clinical impact of routine biopsies of the gastric antrum and body显示文摘 | Sipponen P Stolte M | | 0，，： | 1 |
| 20 | Crohnrs disease activity assessed by fecal calprotectin and lactoferrin:cor- relation with Crohns disease activity index and endoscop- ic findings显示文摘 | Sipponen T Savilahti E Kolho KL | 2008 | Inflamm Bowel Dis2008，14，1： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员